Abstracts tagged "genetics"

Abstract Number: 0904 • ACR Convergence 2024
Defining the Function of Disease Variants with CRISPR Editing and Multimodal Single Cell Sequencing
Yuriy Baglaenko¹, MIchelle Curtis², Majd Al Suqri³, Ryan Agnew³, Aparna Nathan⁴, Hafsa Mire⁴, Annelise Yoo Mah-Som³, David Liu⁵, Gregory Newby⁶ and Soumya Raychaudhuri³, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Broad Institute, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA, ⁵Broad Institute, Cambridge, MA, ⁶Johns Hopkins, Baltimore, MD
Background/Purpose: Genetic studies have identified thousands of individual disease-associated non-coding alleles, but identification of the causal alleles and their functions remain critical bottlenecks. Even though…
Abstract Number: 1424 • ACR Convergence 2024
Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD
Panagiotis Panagopoulos¹, Loukas chatzis², Vasiliki Kitsiou³, Katerina Tarassi³, Eirini Chatzinikita⁴, Katerina Malagari⁵, Theodoros Vassilakopoulos⁴, Alexandra Tsirogianni³, Andreas Goules⁶ and Athanasios Tzioufas⁷, ¹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ³Immunology and Histocompatibility Department, Evangelismos General Hospital, Athens, Greece, ⁴Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁵2nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Genetic studies in various systemic autoimmune rheumatic diseases (SARDs) support that human leukocyte antigen (HLA) class II alleles are associated with specific autoimmune disorders…
Abstract Number: 2202 • ACR Convergence 2024
Evolving Phenotypic and Genotypic Spectrum of Human ISG15 and USP18 Deficiencies
Alhanouf Alsaleem¹, Wafaa Abdulghaffar², Lujain Akbar³, Meshal Alhassan⁴, Fatimah Alkhars⁵ and Sulaiman Al-Mayouf⁶, ¹KFSH&RC, Riyadh, Saudi Arabia, ²KFSHRC, RIYADH, RIYADH, ³RIYADH, RIYADH, Saudi Arabia, ⁴Imam Abdulrahman Bin Faisal University, DAMMAM, ⁵Maternity and children hospital, ALHASSA, ⁶KFSHRRC, Riyadh, Saudi Arabia
Background/Purpose: Loss of negative regulator in ISG15 and USP18 results in recently described immunodysregulatory disorders with diversity of clinical characteristics related to enhanced IFN-a/b immunity.…
Abstract Number: 0907 • ACR Convergence 2024
Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol
Niamh Fanning¹, Murray Cadzow², Ruth Topless³, Chris Frampton⁴, Nicola Dalbeth⁵, Tony Merriman⁶ and Lisa Stamp⁴, ¹University of Otago, Christchurch, New Zealand, ²University of Otago, Dunedin 9054, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
Abstract Number: 1761 • ACR Convergence 2024
Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry
Sabrina George¹, Hannah C Ainsworth², Kaiyu Jiang³, Gilad Barshad⁴, Adam He⁴, Edward Rice⁴, Carl D Langerfeld², Charles G Danko⁴ and James N Jarvis³, ¹University at Buffalo Jacobs School of Medicine, Buffalo, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Cornell University Baker School of Veterinary Medicine, Ithaca, NY
Background/Purpose: - Numerous juvenile idiopathic arthritis (JIA) risk loci have been identified, overwhelmingly from cohorts of children of European ancestry (EA). The extent to which…
Abstract Number: 2282 • ACR Convergence 2024
Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response
M. Elaine Husni, Judy Zhang, Jean Lin, Yuxuan Jin and Unnikrishnan Chandrasekharan, Cleveland Clinic, Cleveland, OH
Background/Purpose: The development of a personalized medicine approach to identify responders and non-responders to tumor necrosis factor alpha (TNFα) inhibiting agents for rheumatoid arthritis (RA)…
Abstract Number: 0908 • ACR Convergence 2024
Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci
Nina Oparina¹, Sarah Reid², Ahmed Sayadi³, Maija-Leena Eloranta⁴, Martina Frodlund⁵, Karoline Lerang⁶, Andreas Jönsen⁷, Solbritt Rantapaa-Dahlqvist⁸, Anders Bengtsson⁷, Anna Rudin⁹, Øyvind Molberg¹⁰, Christopher Sjowall¹¹, Lars Rönnblom⁴ and Dag Leonard⁴, ¹UU, Uppsala, Sweden, ²Uppsala University, Medical Sciences, Uppsala, Sweden, ³Uppsala, Uppsala, Sweden, ⁴Uppsala University, Uppsala, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶Oslo University, Oslo, Norway, ⁷Lund University, Lund, Sweden, ⁸Umeå University, Umeå, Sweden, ⁹Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ¹⁰Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹¹Linköping University, Linköping, Sweden
Background/Purpose: Heritability of SLE is high and more than 200 genetically associated SLE risk loci were identified. Part of them are specific and associate with…
Abstract Number: 1766 • ACR Convergence 2024
STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility
Conor Gruber¹, Angelica Lee², Sofija Buta², Marta Martin Fernandez², Veronique Houdouin³, Jean-Laurent Casanova⁴, Alice Hadchouel⁵, Jacinta Bustamante⁵ and Dusan Bogunovic², ¹Mount Sinai Hospital, New York, NY, ²Columbia University, New York, NY, ³Robert Debré Hospital, Paris, France, ⁴Rockefeller University, New York, NY, ⁵Hôpital Necker-Enfants Malades, Paris, France
Background/Purpose: Type I IFN (IFN-I) signaling is a potent inflammatory pathway fundamental to antiviral immunity. In humans, loss of IFN-I activity underlies severe viral disease,…
Abstract Number: 2373 • ACR Convergence 2024
The Construction and Validation of Sub-phenotype-specific Genetic Risk Scores in Systemic Lupus Erythematosus: A Novel Approach Using Large-scale Biobank Data
Sarah Reid¹, Johanna Sandling², Pascal Pucholt³, Ahmed Sayadi⁴, Martina Frodlund⁵, Karoline Lerang⁶, Andreas Jönsen⁷, Christopher Sjowall⁸, Iva Gunnarsson⁹, Ann-Christine Syvänen², Anders Bengtsson⁷, Øyvind Molberg¹⁰, Elisabet Svenungsson¹¹, Anna Rudin¹², Solbritt Rantapaa-Dahlqvist¹³, Lars Rönnblom² and Dag Leonard², ¹Uppsala University, Medical Sciences, Uppsala, Sweden, ²Uppsala University, Uppsala, Sweden, ³Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala university, Uppsala, Sweden, ⁴Uppsala, Uppsala, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶Oslo University Hospital, Oslo, Norway, ⁷Lund University, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Karolinska Institute, Stockholm, Sweden, ¹⁰Oslo University Hospital, Department of Rheumatology, Oslo, Nepal, ¹¹Karolinska Institutet, Stockholm, Sweden, ¹²Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ¹³Umeå University, Umeå, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a heterogeneous clinical picture. This study aimed to link genetic SLE predisposition with relevant clinical…
Abstract Number: 0055 • ACR Convergence 2024
Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis
Katharine moosic¹, Thomas Olson², Mark Freijat³, samara khalique⁴, Cait Hamele¹, Bryna Shemo¹, Jesse Boodoo⁵, William Baker⁶, Gitanjali Khurana⁷, Matthew Schmachtenberg⁸, Tristin Duffy⁸, Aakrosh Ratan¹, Erika Darrah⁹, Felipe Andrade¹⁰, Marieke Jones⁸, Kristine Olson², David Feith¹, Thomas Loughran¹ and Donald Kimpel¹, ¹University of Virginia, Charlottesville, VA, ²Virginia Commonwealth University, Richmond, VA, ³Flow Rheumatology, Scottsdale, AZ, ⁴Carilion Clinic/ VirginiaTech, Salem, VA, ⁵Sarasota Arthritis Center, Sarasota, FL, ⁶Atrium Health, Charlotte, NC, ⁷University of Virginia, CROZET, VA, ⁸University of Virginia, Charlottesville, ⁹Johns Hopkins University, Baltimore, MD, ¹⁰The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
Abstract Number: 0910 • ACR Convergence 2024
Reduced Adenosine-Mediated Regulatory Activity Exacerbated by an NT5E Loss of Function Mutation Is Linked to Tissue Inflammation and Hypertension in Systemic Lupus Erythematosus
Katherine Owen¹, Isaac Peabody², Mikhail Olferiev³, Tyson Dawson², Prathyusha Bachali⁴, Peter Kasson⁵, Amrie Grammer⁶, Mary Crow³ and Peter Lipsky², ¹RILITE, Charlottesville, VA, ²Ampel Biosolutions, Charlottesville, VA, ³Hospital for Special Surgery, New York, NY, ⁴AMPEL BioSolutions, Redmond, WA, ⁵University of Virginia, Charlottesville, VA, ⁶AMPEL LLC, Charlottesville, VA
Background/Purpose: Adenosine is a purine nucleoside generated by the enzymatic activity of CD73/NT5E, that functions as an endogenous regulator of the immune system critical for…
Abstract Number: 1773 • ACR Convergence 2024
Divergent Genetic Architecture in Boys and Girls with NEMO-deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) Implies Role for Wildtype Effector Cells
Adriana Almeida de Jesus¹, Kip Friend², Bin Lin³, Eric Karlins⁴, Colton McNinch⁴, Sara Alehashemi⁵, Keith Kauffman⁶, FARZANA BHUYAN³, Taylor Newbolt⁶, Andrea Bohrer⁷, Andre Rastegar³, Sophia Park³, Dana Kahle³, Jacob Mitchell³, Amanda Chen³, Sofia Torreggiani⁸, Kader Cetin Gedik⁹, Katsiaryna Uss², Amer Khojah¹⁰, Eveline Wu¹¹, Christiaan Scott¹², Timothy Ronan Leahy¹³, Emma MacDermott¹⁴, Orla Killeen¹⁵, Thaschawee Arkachaisri¹⁶, Brian Nolan¹⁷, Zoran Gucev¹⁸, Kathryn Cook¹⁹, Vafa Mammadova²⁰, Gulnara Nasrullayeva²⁰, Mariana Correia Marques²¹, Abigail Bosk²², Seza Ozen²³, Scott Canna²⁴, Maude Tusseau²⁵, Emilie Chopin²⁶, Guilaine Boursier²⁷, Veronique Hentgen²⁸, Ines Elhani²⁹, Mario Sestan³⁰, Marija Jelusic³¹, Danielle Fink³², Douglas Kuhns³², Clifton Dalgard³³, Alexandre Belot³⁴, Timothy Moran¹¹, Katherine Meyer-Barber⁷, Andrew Oler⁴, Daniel Barber⁶ and Raphaela Goldbach-Mansky³⁵, ¹NIAID, NIH, Silver Spring, MD, ²Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Bethesda, MD, ³TADS, NIAID, NIH, Bethesda, MD, ⁴BCBB, NIAID, NIH, Bethesda, MD, ⁵NIH/NIAID/TADS, Potomac, MD, ⁶T Lymphocyte Biology Section, LPD, NIAID, NIH, Bethesda, MD, ⁷Inflammation and Innate Immunity Unit, LCIM, NIAID, NIH, Bethesda, MD, ⁸University Of Maryland Baltimore, Baltimore, MD, ⁹Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Pittsburgh, PA, ¹⁰Umm Al-Qura University, Makkah, Saudi Arabia, ¹¹University of North Carolina School of Medicine, Chapel Hill, NC, ¹²University of Cape Town, Cape Town, South Africa, ¹³Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, ¹⁴CHI Crumlin, Dublin, Dublin, Ireland, ¹⁵Children's Health Ireland, Dublin, Ireland, ¹⁶KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, ¹⁷Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁸University Children's Hospital, Skopje, Macedonia, ¹⁹Akron Children's Hospital, Akron, OH, ²⁰Azerbaijan Medical University, Baku, Azerbaijan, ²¹National Institutes of Health, Bethesda, MD, ²²Children's National Hospital, Bethesda, DC, ²³Department of Pediatrics, Hacettepe University, Ankara, Turkey, ²⁴Children's Hospital of Philadelphia, Philadelphia, PA, ²⁵RAISE, Hospices Civils de Lyon, Lyon, France, ²⁶Hospices Civils de Lyon, Lyon, France, ²⁷University of Montpellier, Montpellier, ²⁸Laboratoire de Génétique des Maladies Rares et Autoinflammatoires, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CEREMAIA, CHU de Montpellier, Univ Montpellier, Montpellier, France, Le Chesnay, France, ²⁹Department of Internal Medicine, Caen University Hospital, Caen, France, Caen, France, ³⁰University of Zagreb School of Medicine University Hospital Centre Zagreb, Zagreb, Croatia, ³¹University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ³²Collaborative Clinical Research Branch, NIAID, NIH, Bethesda, MD, Bethesda, MD, ³³The American Genome Center, Department of Anatomy, Physiology & Genetics, Uniformed Services University, Bethesda, MD, ³⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ³⁵Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Potomac, MD
Background/Purpose: Splice-site variants in X-linked IKBKG cause NEMO-deleted exon5 autoinflammatory syndrome (NEMO-NDAS); a pseudogene (IKBKGP1) complicates genetic diagnosis. NEMO-NDAS is four times more common in…
Abstract Number: 2387 • ACR Convergence 2024
Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
Madeline Alizadeh¹, Vishnuprabu Pandian¹, Christele Felix², Andrra Nimoni², Jasmin Divers³, Timothy Niewold² and Ashira Blazer¹, ¹University of Maryland Baltimore, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Compared to Apolipoprotein L1 (APOL1) low risk genotype (LRG) patients, APOL1 (HRG) has been shown to increase the risk of chronic kidney disease in…
Abstract Number: 0114 • ACR Convergence 2024
Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cécile Yelnik¹, shruti chaturvedi², Julien Labreuche³, Xiang-Zuo Pan², H Michael Belmont⁴, Nina Kello⁵, Paul Fortin⁶, David Branch⁷, Yu Zuo⁸, Rohan Willis⁹, Robert Brodsky², Jane Salmon¹⁰, Maria Laura Bertolaccini¹¹, Hannah Cohen¹², Michelle Petri¹³ and Doruk Erkan¹⁰, and on behalf of APS ACTION, ¹lille university, Lille, France, ²John Hopkins University, Baltimore, MD, ³Lille University Hospital, Lille, France, ⁴NYU Langone Health, New York, NY, ⁵Northwell Health, Brooklyn, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁷University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Texas Medical Branch, Galveston, TX, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹King's College London, London, United Kingdom, ¹²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We previously reported that markers of complement activation, specifically elevated C4d levels and positive modified HAM (mHAM) test, are associated with a higher risk…
Abstract Number: 0912 • ACR Convergence 2024
Next-Generation Sequencing in Molecular Genetics of Adult-Onset Still’s Disease: Data from 23 Patients and Literature Review
Belén Atienza-Mateo¹, Diana Prieto-Peña¹, Eztizen Labrador-Sánchez², Natalia Palmou Fontana¹, Rafael Benito Melero-Gonzalez³, Fred Anton Pages⁴, Carmen Alvarez Reguera⁵, Nerea Paz-Gandiaga⁶ and Ricardo Blanco-Alonso⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ²Hospital General de La Rioja, Logroño, Spain, ³CHU Ourense, O Carballino, Spain, ⁴Complejo Asistencial De Segovia, Segovia, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Department of Genetics, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Molecular genetic techniques are becoming increasingly essential tools for the diagnosis of monogenic systemic autoinflammatory diseases (SAIDs). However, their role in the diagnosis of…

1
2
3
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.